Incyte corporation INCY.US Overview
INCY AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
INCY Current Performance
-2.47%
Incyte corporation
-1.83%
Avg of Sector
-0.40%
S&P500
INCY Key Information
INCY Revenue by Segments
Browsing restrictions can be lifted for a fee.
INCY Net Income
Browsing restrictions can be lifted for a fee.
INCY Cash Flow
Browsing restrictions can be lifted for a fee.
INCY Profit Margin
Browsing restrictions can be lifted for a fee.
INCY PE Ratio River
Browsing restrictions can be lifted for a fee.
INCY Financial Forecast
Browsing restrictions can be lifted for a fee.
INCY Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
INCY Profile
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Price of INCY
INCY FAQ
When is INCY's latest earnings report released?
The most recent financial report for Incyte corporation (INCY) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating INCY's short-term business performance and financial health. For the latest updates on INCY's earnings releases, visit this page regularly.
Where does INCY fall in the P/E River chart?
According to historical valuation range analysis, Incyte corporation (INCY)'s current price-to-earnings (P/E) ratio is 549.95, placing it in the Watch zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of INCY?
According to the latest financial report, Incyte corporation (INCY) reported an Operating Profit of 205.17M with an Operating Margin of 19.49% this period, representing a growth of 123.26% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is INCY's revenue growth?
In the latest financial report, Incyte corporation (INCY) announced revenue of 1.05B, with a Year-Over-Year growth rate of 19.53%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does INCY have?
As of the end of the reporting period, Incyte corporation (INCY) had total debt of 37.12M, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does INCY have?
At the end of the period, Incyte corporation (INCY) held Total Cash and Cash Equivalents of 1.94B, accounting for 0.34 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does INCY go with three margins increasing?
In the latest report, Incyte corporation (INCY) achieved the “three margins increasing” benchmark, with a gross margin of 93%%, operating margin of 19.49%%, and net margin of 15%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess INCY's profit trajectory and future growth potential.
Is INCY's EPS continuing to grow?
According to the past four quarterly reports, Incyte corporation (INCY)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.82. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of INCY?
Incyte corporation (INCY)'s Free Cash Flow (FCF) for the period is 262.9M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 25.63% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of INCY?
The latest valuation data shows Incyte corporation (INCY) has a Price-To-Earnings (PE) ratio of 549.95 and a Price/Earnings-To-Growth (PEG) ratio of -1.2. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.